Cargando…

The New NCI Precision Medicine Trials

Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice) have proven the principle that studying targeted therapies on a large s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Harris, Lyndsay N., Blanke, Charles D., Erba, Harry P., Ford, James M., Gray, Robert J., LeBlanc, Michael L., Hu-Lieskovan, Siwen, Litzow, Mark R., Luger, Selina M., Meric-Bernstam, Funda, O'Dwyer, Peter J., Othus, Megan K.D., Politi, Katerina, Shepherd, Lois E., Allegra, Carmen J., Chen, Helen X., Ivy, S. Percy, Korde, Larissa A., Little, Richard F., McShane, Lisa M., Moscow, Jeffrey A., Patton, David R., Thurin, Magdalena, Yee, Laura M., Doroshow, James H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690084/ https://www.ncbi.nlm.nih.gov/pubmed/37531248 http://dx.doi.org/10.1158/1078-0432.CCR-23-0917

Ejemplares similares

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
por: Flaherty, Keith T, et al.
Publicado: (2020)

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)
por: Meric-Bernstam, Funda, et al.
Publicado: (2023)

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial
por: Chen, Alice P., et al.
Publicado: (2021)

TPM, FPKM, or Normalized Counts? A Comparative Study of Quantification Measures for the Analysis of RNA-seq Data from the NCI Patient-Derived Models Repository
por: Zhao, Yingdong, et al.
Publicado: (2021)

Whole Genome Sequencing in Cancer Clinics
por: Chen, Ken, et al.
Publicado: (2014)

Enrollment of adolescent and young adult patients newly diagnosed with cancer in NCI CTEP‐sponsored clinical trials before and after launch of the NCI National Clinical Trials Network
por: Sankaran, Hari, et al.
Publicado: (2022)

NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
por: Reinhold, William C., et al.
Publicado: (2014)

Personalized cancer therapy—leveraging a knowledge base for clinical decision-making
por: Dumbrava, Ecaterina Ileana, et al.
Publicado: (2018)

Pharmacogenomics of in vitro response of the NCI-60 cancer cell line panel to Indian natural products
por: Sankaran, Hari, et al.
Publicado: (2022)

Targeting translation initiation in breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2014)

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
por: Flaherty, Keith T., et al.
Publicado: (2020)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer
por: Akcakanat, Argun, et al.
Publicado: (2009)

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
por: Mansfield, A. S., et al.
Publicado: (2022)

Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)

What does PD-L1 positive or negative mean?
por: Ribas, Antoni, et al.
Publicado: (2016)

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems–based Resource
por: Morris, Joel, et al.
Publicado: (2023)

NCI Imaging Data Commons
por: Fedorov, Andrey, et al.
Publicado: (2021)

Concerted changes in transcriptional regulation of genes involved in DNA methylation, demethylation, and folate-mediated one-carbon metabolism pathways in the NCI-60 cancer cell line panel in response to cancer drug treatment
por: Krushkal, Julia, et al.
Publicado: (2016)

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023)

Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel
por: Shen, Chan, et al.
Publicado: (2016)

Efficacy of Quality Criteria to Identify Potentially Harmful Information: A Cross-sectional Survey of Complementary and Alternative Medicine Web Sites
por: Walji, Muhammad, et al.
Publicado: (2004)

Molecular genomic features associated with in vitro response of the NCI‐60 cancer cell line panel to natural products
por: Krushkal, Julia, et al.
Publicado: (2020)

Strategies for improving the management of immune-related adverse events
por: Naing, Aung, et al.
Publicado: (2020)

Overview and Utilization of the NCI Thesaurus
por: Fragoso, Gilberto, et al.
Publicado: (2004)

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells
por: Zhao, Ming, et al.
Publicado: (2019)

Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing
por: Leighton, Jake, et al.
Publicado: (2022)

Adapting a Natural Language Processing Tool to Facilitate Clinical Trial Curation for Personalized Cancer Therapy
por: Zeng, Jia, et al.
Publicado: (2014)

Antibody-drug conjugates in lung cancer: dawn of a new era?
por: Coleman, Niamh, et al.
Publicado: (2023)

Ploidy-Seq: inferring mutational chronology by sequencing polyploid tumor subpopulations
por: Malhotra, Ankit, et al.
Publicado: (2015)

İNTERNET 20'NCİ YAŞINI KUTLUYOR
Publicado: (2009)

İnternet 20`nci yaşını kutluyor
Publicado: (2009)

CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
por: Mao, Yong, et al.
Publicado: (2013)

Iodine Nanoparticles (Niodx(™)) for Radiotherapy Enhancement of Glioblastoma and Other Cancers: An NCI Nanotechnology Characterization Laboratory Study
por: Hainfeld, James F., et al.
Publicado: (2022)

Exosomes as a predictor tool of acquired resistance to melanoma treatment
por: Goedert, Lucas, et al.
Publicado: (2014)

Report from an NCI Roundtable: Cancer Prevention in Primary Care
por: Samimi, Goli, et al.
Publicado: (2022)

CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts
por: Huang, Licai, et al.
Publicado: (2022)

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016)

Recombination phenotypes of the NCI-60 collection of human cancer cells
por: Stults, Dawn M, et al.
Publicado: (2011)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_03ppe7r13ph4gtovq8fss8etit